Clinical trial · Observational
Retrospective Epidemiological Study of Locally Advanced Non Small Cell Lung Cancer Patients in Brazil
NCT03836469CI-TRIAL-00074154RELANCEcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RELANCE is a large multi-institutional study that aims to retrospectively collect information about diagnostic, treatment and outcome of patients diagnosed with locally advanced NSCLC in Brazil. It is hypothesized that there is a great heterogeneity in treatment patterns owing to inequities in access to adequate staging methods, optimal treatment and multidisciplinary teams in Brazil.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer, Non-small Cell | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- Up to June 30, 2018
- description
- defined as time from diagnosis to death of any cause;
Secondary outcomes (2)
- measure
- Progression free survival
- timeFrame
- Up to June 30, 2018
- description
- defined as time from any line of treatment to progression of the disease or death of any cause
- measure
- Time to next treatment
- timeFrame
- Up to June 30, 2018
- description
- defined as time from start of the any treatment to the beginning of a second therapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients aged 18 years or older; 2. Histologically or cytological diagnosis of NSCLC in the period of January 2015 to December 2016; 3. Locally Advanced NSCLC defined as clinical stage IIIA and IIIB according to 7th Edition TNM Staging System; 4. Any NSCLC histological subtype and molecular mutation; 5. Any Eastern Cooperative Oncology Group (ECOG) Performance Status (0 to 4) at diagnosis; 6. Patients assigned by treating physician to any therapy or palliative care; 7. Access to patient medical chart for data collection. Exclusion Criteria: 1. Small cell lung cancer and non-invasive NSCLC; 2. Synchronic NSCLC or second primary tumour in the last 5 years (except non-melanoma skin cancer).
References
Publications (0)
Data not yet available
No reference posted for this study.